🔬 New PSMA-PET–based #prostatecancer risk classification (PROMISE; PPP3 nomograms) outperforms or matches existing risk models in predicting overall survival.
🔸Karpinski et al | @TheLancetOncol | #PCSM
🔗 ascopost.com/news/march-202…
English
The ASCO Post
34.7K posts
The ASCO Post
@ASCOPost
News and views from the world of clinical oncology and hematology
Huntington, NY Katılım Aralık 2009
4.5K Takip Edilen62.1K Takipçiler
💉 Phase 3️⃣ RECITE data: Romiplostim significantly improved #chemotherapy-induced thrombocytopenia in patients with GI cancers—helping patients stay on full-dose treatment.
🩺 @HannyAlSamkari | @NEJM | #GIcancer
🔗 ascopost.com/news/march-202…
English
#ASCOAI: Insights from the latest @AmerMedicalAssn survey:
📊 81% of physicians report using #AI
📊 76% say it enhances patient care
📊 70% see it helping reduce burnout
➡️ Highlights growing use, optimism, & the need for strong governance and training
ascoai.org/articles/2026/…
English
🩸 New data highlight the value of optical genome mapping in acute #leukemia—identifying key genetic alterations missed by conventional assays and refining diagnosis. 🧬
🔹 Tara Spence, PhD, FCCMG, FACMG of #UBC | @JMDiagn | #leusm
🔗 ascopost.com/news/march-202…
English
🫁 Phase III CAMPASS trial: PD-L1 inhibitor benmelstobart + anlotinib demonstrated a significant PFS benefit vs pembrolizumab in PD-L1+ advanced #NSCLC—supporting further investigation as a first-line option.
🔸 Zhong et al | @TheLancetOncol | #LCSM
🔗 ascopost.com/news/march-202…
English
💻 #ASCOAI: #AI meets molecular #neuropathology.
🧠 Neuropath-AI uses histology to infer molecular features and classify CNS tumors—model is basis for a clinically applicable, deep-learning assistant
🔹 H. Lalchungnunga, PhD | @TheLancet | #BrainTumors
🔗 ascoai.org/articles/2026/…
English
📊 KEYNOTE-937 findings in #HCC:
• No RFS benefit with adjuvant pembrolizumab vs placebo
• Median RFS: 46.7 vs 45.5 months (HR = 1.06)
• No new safety signals observed
🩺 Presented by Stephen Lam Chan, MD, FRCP at #GI26
🔗 ascopost.com/news/march-202…
English
🚨 The @US_FDA has launched a unified Adverse Event Monitoring System (AEMS) to modernize safety tracking and enable real-time reporting across regulated drugs and products.
Learn more about the new system ➡️ ascopost.com/news/march-202…
English
🚺 A global study of 264 million deaths across 20 countries found that female reproductive cancers (#breastcancer & #gynecologiccancers) reduce women’s survival advantage over men ages 35–60.
🔸 Vladimir Canudas-Romo, PhD of @ANUmedia
Read the report 👉 ascopost.com/news/march-202…
English
🖥️ #ASCOAI: #AI + digital #pathology may refine #prostatecancer risk stratification.
🚹 A multimodal AI biomarker demonstrated improved prediction of recurrence & distant metastasis compared with NCCN, CPG risk models.
👩⚕️ Dr. Anna Clare Wilkins at #GU26
🔗 ascoai.org/articles/2026/…
English
💊 Rezatapopt, an investigational oral p53 reactivator, demonstrated proof-of-concept activity in patients with TP53 Y220C–mutated solid tumors in a phase I trial.
🔹 Alison Schram, MD of @MSKCancerCenter | @NEJM
🔗 ascopost.com/news/march-202…
English
📊 Phase II CAREMM-001 study findings in newly diagnosed #multiplemyeloma:
✅ 100% MRD negativity at 3 months
✅ ️ CR rate increased to 94.4% at follow-up
✅ No disease progression reported
🔹 Yan et al | @JCO_ASCO
🔗 ascopost.com/news/march-202…
English
👁️ Phase II CHOPIN trial: Adding nivolumab + ipilimumab to percutaneous hepatic perfusion significantly improved progression-free survival in patients with metastatic #uvealmelanoma.
🔸 van den Hoek et al | @TheLancetOncol
🔗 ascopost.com/news/march-202…
English
🖥️ #ASCOAI: In a comparative analysis of #AI pathology tools:
• Highest agreement for HER2 3+ (88% agreement)
• Lower agreement in borderline categories (eg, 1+ vs 2+)
➡️ Insights into where AI tools may need refinement.
@ModernPathology @CancerResrch
ascoai.org/articles/2026/…
English
📊 Study findings in BRCA1/2 carriers:
• 5-year #breastcancer risk after ovarian cancer: 4.4% (HR = 0.18)
• 15-year risk: 11.5%
• Significantly lower than BRCA carriers without #ovariancancer
👨⚕️ Steven A. Narod, MD | @JCO_ASCO
🔗 ascopost.com/news/march-202…
English
🫁 New research suggests severe viral respiratory infections—such as COVID-19 or influenza—may prime the lungs for #cancer development.
💉 Vaccination may help reduce that risk.
🔹 Wei Qian et al | @CellPressNews | #LCSM
Read the full report ➡️ ascopost.com/news/march-202…
English
📣 @StanfordCancer has named Vivek Subbiah, MD (@VivekSubbiah) as inaugural associate director for drug development and #precisiononcology, where he will lead efforts to expand early-phase #cancer trials and precision therapies.
🔗 ascopost.com/news/march-202…
English
🖥️ This week in #ASCOAI & #cancer research:
• @US_FDA Breakthrough Device Designation for a generative #AI radiology model
• AI comparison for HER2 scoring in #breastcancer
• Predictive AI models in #pancreaticcancer and #glioma
🎥 Watch the brief: ascoai.org/videos/weekly-…
English
🩸 Do androgen-receptor pathway inhibitors increase bleeding risk when combined with anticoagulants?
A new real-world study suggests no significant increase in bleeding or clotting risk in patients with advanced #prostatecancer.
🔹 Wang et al
Read here ➡️ ascopost.com/news/march-202…
English
🩺 #GU26: Amar Kishan, MD (@AmarUKishan) discusses new evidence on the role of hormone therapy combined with postoperative radiotherapy for localized #prostatecancer after prostatectomy. #PCSM
🎥 Watch the video: ascopost.com/videos/2026-as…
English